Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults

Journal of Clinical Pharmacology

Volumn 52, Issue 1, 2012, Pages 18-28

  Zhang, Shuzhong ^a   Shi, Rong ^b   Li, Chunze ^a   Parivar, Kourosh ^a   Wang, Diane D ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

biologics; body size based dosing; body surface area; body weight; Fixed dosing; monoclonal antibodies; peptide; pharmacodynamics; population pharmacokinetics; protein

Indexed keywords

ABATACEPT; ANGIOPEPTIN; DAPTOMYCIN; DEGARELIX; DEHYDRODIDEMNIN B; EMFILERMIN; ENFUVIRTIDE; ETANERCEPT; HUMAN GROWTH HORMONE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; ONERCEPT; PEG INTRON A; PEGINESATIDE; PEGINTERFERON ALPHA2B; PEPTIDES AND PROTEINS; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; UROFOLLITROPIN;

ADULT; ARTICLE; BODY SIZE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE; DRUG EXPOSURE; FIXED DOSING; HUMAN; SIMULATION; SINGLE DRUG DOSE;

ADULT; AREA UNDER CURVE; BIOLOGICAL AGENTS; BODY SIZE; COMPUTER SIMULATION; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PEPTIDES; PROTEINS;

EID: 84855425541     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010388648     Document Type: Article

References (22)

1. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009 ; 49: 1012-1024
2. Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab. 2009 ;:
3. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008 ; 84: 548-558
4. Hermanussen M, Danker-Hopfe H, Weber GW. Body weight and the shape of the natural distribution of weight, in very large samples of German, Austrian and Norwegian conscripts. Int J Obes Relat Metab Disord. 2001 ; 25: 1550-1553 (Pubitemid 32977876)
5. Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol. 2007 ; 47: 1408-1420 (Pubitemid 47624599)
6. Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J. 2006 ; 8: E552 - E563
7. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003 ; 73: 348-365 (Pubitemid 36403595)
8. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2004 ; 48: 2799-2807 (Pubitemid 38989139)
9. Tornoe CW, Agerso H, Nielsen HA, Madsen H, Jonsson EN. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME. J Pharmacokinet Pharmacodyn. 2004 ; 31: 441-461 (Pubitemid 41175365)
10. Goggin T, Nguyen QT, Munafo A. Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer. Br J Clin Pharmacol. 2004 ; 57: 576-585 (Pubitemid 38582177)
11. Mould DR, Zhang X, Nieforth K, Salgo M, Buss N, Patel IH. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther. 2005 ; 77: 515-528 (Pubitemid 40824965)
12. Chakraborty A, Natarajan J, Guilfoyle M, Morgan N, Vercammen E, Cheung W. Population pharmacokinetics of erythropoietin in critically ill subjects. J Clin Pharmacol. 2005 ; 45: 193-202 (Pubitemid 40490443)
13. Hayashi N, Kinoshita H, Yukawa E, Higuchi S. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. Br J Clin Pharmacol. 1998 ; 46: 11-19 (Pubitemid 28308419)
14. Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol. 2008 ; 48: 43-52 (Pubitemid 350292274)
15. Troconiz IF, Cendros JM, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet. 2009 ; 48: 51-62
16. Zhou H, Chen TL, Marino M, et al. Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. Br J Clin Pharmacol. 2000 ; 50: 543-552 (Pubitemid 32010015)
17. Glatt S, Fuseau E, Buraglio M, Nguyen QT. Population pharmacokinetics of onercept in healthy subjects. Clin Pharmacokinet. 2005 ; 44: 1295-1304 (Pubitemid 41832570)
18. Jen JF, Glue P, Ezzet F, et al. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin Pharmacol Ther. 2001 ; 69: 407-421 (Pubitemid 32554546)
19. Nalda-Molina R, Valenzuela B, Ramon-Lopez A, Miguel-Lillo B, Soto-Matos A, Perez-Ruixo JJ. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects. Cancer Chemother Pharmacol. 2009 ; 64: 97-108
20. Girard P, Nony P, Erhardtsen E, et al. Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost. 1998 ; 80: 109-113 (Pubitemid 28353508)
21. Klitgaard T, Nielsen JN, Skettrup MP, Harper A, Lange M. Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. Growth Horm IGF Res. 2009 ; 19: 463-470
22. Karlsson MO, Wade JR, Loumaye E, Munafo A. The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women. Br J Clin Pharmacol. 1998 ; 45: 13-20 (Pubitemid 28062848)